Jennison Associates
RVMD icon

Jennison Associates’s Revolution Medicines RVMD Stock Holding History

Jennison Associates’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9M Buy
307,377
+2,117
+0.7% +$214K 0.02% 286
2025
Q4 		$24.3M Buy
+305,260
New +$20M 0.01% 310
2020
Q2 		– Sell
-200,490
Closed -$4.39M – 693
2020
Q1 		$4.39M Buy
+200,490
New +$5.55M 0.01% 409

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates's RVMD Position: Q1 2026 in Review

Jennison Associates increased its Revolution Medicines (RVMD) stake by 0.69% in Q1 2026, buying an estimated $214K and bringing the position to 307,377 shares worth $29.9M. The position accounts for 0.02% of the portfolio, ranked #286.

Jennison Associates first reported a position in RVMD in Q1 2020 and has held it in 3 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Jennison Associates held 307,377 shares of Revolution Medicines worth $29.9M as of Q1 2026.
  • Jennison Associates bought 2,117 Revolution Medicines shares in Q1 2026, an estimated $214K.
  • Revolution Medicines made up 0.02% of Jennison Associates's portfolio in Q1 2026, its #286 holding.
  • Jennison Associates first reported a position in Revolution Medicines in Q1 2020 and has held it in 3 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.